to the pork industry compared to the control group on all occasions. This explains the widening gap in average weights between the vaccinated groups and control group at d 113 and d 143 on-test. All groups did not exhibit any significant difference in ADG from Day 113 to Day 143 and at off-test which indicates that significant difference in growth rates occurs between Day 0 and Day 113. No differences in mortality rate were noted between any of the treatment groups. However, the two vaccinated groups had 3% lower mortality compared to the control group. We believe that the absence of statistical difference among the treatments is due to the greater variability as a result of a respiratory disease outbreak during the trial. A clinical outbreak of bacterial disease due to Haemophilus parasuis was noted in two nursery groups. Additionally, an outbreak of respiratory disease due to Actinobacillus pleuropneumoniae was noted in one finisher group. In conclusion, both commercial PCV2 vaccines were effective in improving the growth performance of pigs from weaning to finishing as shown by heavier weights and higher ADG of the vaccinated groups. There was no statistically significant difference between the two vaccines in terms of the parameters measured. However, pigs given the 2-dose vaccine were 2.6 lbs heavier than those given the 1-dose vaccine at d 143 after weaning. Table 1. Effects of PCV2 Vaccine on grow performance and mortality rate Vaccine Main Effect Sex Main Effect Item Control 1-dose1 2-dose2 Barrow P-values Difference Gilt control-1dose control2dose 1dose2dose Barrow-Gilt Vaccine Sex Weight, lb 19.1 19.6 19.3 19.3 19.4 -.05 -0.2 0.3 -0.1 0.24 0.50 Day 113 Day 0 181.8a 188.2ab 190.7b 190.3 183.5 -6.5 -2.5 -2.5 6.7 0.04 <.0001 Day 143 237.3a 244.8b 247.4b 248.7 237.6 -7.6 -2.6 -2.6 11.1 0.03 <.0001 Off-test 256.7 261.8 265.0b 265.3 257.1 -5.1 -3.2 -3.2 8.2 0.05 <.0001 Days On-test a ab 153.2 151.8 151.9 151.2 153.3 1.4 -0.1 -0.1 -2.1 0.08 <.0001 ADG, lb d0-d113 1.44a 1.49b 1.52b 1.51 1.45 -0.06 -0.03 -0.03 0.06 0.02 <.0001 d0-d143 1.53a 1.58b 1.60b 1.61 1.53 -0.05 -0.02 -0.02 0.08 0.02 <.0001 d0-Market 1.55a 1.60b 1.62b 1.63 1.55 -0.05 -0.02 -0.02 0.08 0.02 <.0001 d113-d143 1.89 1.91 1.94 2.0 1.84 -0.02 -0.03 -0.03 0.16 0.39 <.0001 d113-Market 1.89 1.93 1.95 2.0 1.84 -0.03 -0.02 -0.02 0.16 0.25 <.0001 Mortality, % 11.0 7.8 7.7 8.7 9.0 3.2 0.1 0.1 -0.3 0.42 0.86 a,b Means within the vaccine main effect lacking a common superscript differ P<0.05 1 1-dose was the PCV2 vaccine available from Fort Dodge Administered on week after weaning. 2 2-does was the commercially available vaccine from Intervet administered at weaning and 3 weeks later. 3 A total of 1,470 pigs were randomly assigned at weaning (d 0) to one of the thre vaccine treatments within barrows and gilts. Effect of PCV2 Vaccine on Average Weight (Day 143 On-test) 30.0 Frequency 25.0 20.0 15.0 10.0 5.0 0.0 <140 160 180 200 220 240 260 280 300 320 >320 Weight, lbs Figrue1. Comparative wwight districution of treatment groups at Day 143 on-test September/October 2007 â€˘ Pig Tales 15